Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes

• Published in: Journal of gastroenterology and hepatology Vol. 29; no. 11; pp. 1932 - 1942
• Main Authors: Wen, Shi-Lei, Gao, Jin-Hang, Yang, Wen-Juan, Lu, Yao-Yao, Tong, Huan, Huang, Zhi-Yin, Liu, Zhang-Xu, Tang, Cheng-Wei
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.11.2014
• Subjects: Animals; Celecoxib; cirrhosis; Cyclooxygenase 2 Inhibitors - pharmacology; Cyclooxygenase 2 Inhibitors - therapeutic use; Disease Models, Animal; Down-Regulation - drug effects; Epithelial-Mesenchymal Transition - drug effects; Epithelial-Mesenchymal Transition - genetics; epithelial-to-mesenchymal transition; hepatic fibrosis; hepatocyte; Hepatocytes - physiology; Liver Cirrhosis - chemically induced; Liver Cirrhosis - drug therapy; Liver Cirrhosis - genetics; Liver Cirrhosis - pathology; Liver Cirrhosis, Experimental; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sulfonamides - pharmacology; Sulfonamides - therapeutic use; Thioacetamide; Transforming Growth Factor beta1; hepatocyte; hepatic fibrosis; celecoxib; cirrhosis; epithelial-to-mesenchymal transition

Background and Aim The epithelial–mesenchymal transition (EMT) of hepatocytes is a key step for hepatic fibrosis and cirrhosis. Long‐term administration of celecoxib, a selective cyclooxygenase‐2 (COX‐2) inhibitor, can ameliorate hepatic fibrosis. This research aimed to examine the effect of celecox...